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Abstract Noonan syndrome is a relatively common and 
heterogeneous genetic disorder, including congenital 
heart defect in more than half of the cases. If the defect 
is not large, life expectancy is normal. Here we report on 
a case of an infant with Noonan syndrome and rapidly 
progressive hypertrophic cardiomyopathy with lethal out-
come, in whom we identified a novel mutation in the KRAS 
gene. This heterozygous unclassified missense variant in 
exon 3: c.179G>T (p.Gly60Val) might be associated with 
a lethal form of Noonan syndrome. The malignant clinical 
course of the disease and the lethal outcome in an infant 
only a few months old might be connected to RAS-mi-
togen-activated protein kinase pathway hyperactivation, 
consequently promoting cell growth and proliferation, 
leading to rapidly progressive hypertrophic cardiomyopa-
thy. Further biochemical and functional studies are needed 
to confirm this hypothesis.
Noonan syndrome (NS; http://www.omim.org/entry/1639
50?search=163950&highlight=163950) is a relatively com-
mon genetic disorder with an incidence of 1 per 1000-
2500 live births (1). Clinically it is a very heterogeneous dis-
order, predominantly characterized by dysmorphic facial 
features, congenital heart defect (CHD), post-natal short 
stature, webbed neck, chest deformity, cryptorchidism 
in men, lymphatic dysplasia, variable bleeding disorders, 
and intellectual disability. CHD is present in 50 to 80% of 
affected individuals and it is also very heterogeneous (2). 
Most commonly found are pulmonary valve stenosis with 
or without dysplastic pulmonary valve and hypertrophic 
cardiomyopathy. Providing the CHD is not large, life expec-
tancy is in the normal range (3). NS and CHD are regularly 
connected with germline KRAS mutations. We describe a 
patient with NS and rapidly progressive hypertrophic car-
diomyopathy with lethal outcome, in whom we identified 
a novel mutation in the KRAS gene.
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CaSe rePort
The patient was born to healthy Caucasian non-consan-
guineous parents who already had a healthy 4-year old 
daughter. It was the mother’s second pregnancy, which 
was complicated by polyhydramnios and increased fetal 
nuchal translucency thickness. Chorionic villus biopsy was 
performed and revealed normal male karyotype. Several 
fetal morphology ultrasounds and two fetal echocardiog-
raphy examinations revealed no abnormalities. The labor 
started spontaneously after 33 weeks of pregnancy, the 
delivery was vaginal, and the amniotic fluid was meconium 
stained. Birth weight was 2780 g (95th percentile), length 
48 cm (90th percentile), head circumference 33.5 cm (90th 
percentile), and Apgar score 5/7/8. After birth, diffuse lym-
phedema of the body and several dysmorphic features 
(Figure 1) were identified: frontal bossing, antimongoloid 
palpebral slant, exophthalmos, left sided ptosis, wide na-
sal tip, low set, posteriorly rotated, and dysmorphic ears, 
thickened philtrum, tented upper lip, micrognathia, high 
arched palate, large neck skin fold, posterior low set hair 
line, and right scrotal hernia. Echocardiography was per-
formed due to heart murmur and patent ductus arteriosus 
and mild coarctation of aorta were found; during short fol-
low-up the ductus closed spontaneously and the coarcta-
tion remained unchanged. At the age of 2 weeks, echocar-
diography was repeated and revealed hypertrophy of both 
ventricles, and thickened and dysplastic atrioventricular 
and semilunar valves. In addition, there was also a small 
atrial septal defect with left-to-right shunt and mild aor-
tic coarctation. Ultrasound of the abdomen revealed mild 
right-sided hydronephrosis and ectopic dilated right ure-
ther. Ultrasound of the head showed no structural anom-
alies. Ophthalmologic evaluation was unremarkable. The 
clinical picture highly indicated NS.
DNA sequence analysis from peripheral blood leukocytes 
was performed after the informed consent from parents 
had been received. Sanger sequencing of the entire cod-
ing regions of the genes involved in NS was performed 
at the Department of Human Genetics, Radboud Uni-
versity Medical Centre, Nijmegen. All coding exons and 
flanking intronic sequences of genes involved in NS were 
polymerase chain reaction (PCR)-amplified, and direct se-
quencing was performed on an ABI 3730 automated DNA 
sequencer (Applied Biosystems, Foster City CA, USA). 100 
ng DNA was amplified with Amplitaq Gold 360 Master Mix 
(Life Technologies: Bleiswijk, the Netherlands) in the pres-
ence of 5 pmol of each primer, forward (f ) and reverse (r). 
Cycling conditions were 30 seconds at 95°C, 30 seconds at 
60°C, and 1 minute at 72°C (35 cycles). For the KRAS gene 
the following primer sequencing (5’-3’) were used: exon 
2: gtctgcagtcaactggaatt (f ) and ccaaggaaagtaaagttccc (r), 
FiGure 1. Dysmorphic features of the patient with Noonan 
syndrome at the age of 3 months. (A) antimongoloid palpebral 
slant, left side ptosis, (B) low set, posteriorly rotated, and 
dysmorphic ear. Patient’s images are published with parents’ 
consent.
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exon 3: gcatcttttcaggtgcttag (f ) and acagggatattacctac-
ctc (r), exon 4: ggtgtagtggaaactaggaa (f ) and accaaagc-
caaaagcagtac (r), exon 5: gaacaaaccaggattctagc (f ) and 
gtagttctaaagtggttgcc (r), exon 6: cagttgcctgaagagaaaca (f ) 
and ccaaaactctgggaatactg (r).
A heterozygous unclassified variant in the KRAS gene was 
detected and NS was confirmed. It was a missense variant 
in exon 3: c.179G>T (p.Gly60Val) (Figure 2). Furthermore, 
genotyping of parental DNAs demonstrated that the mu-
tation in the child occurred de novo.
FiGure 2. a novel mutation in exon 3 of the KRAS gene. the cytogenetic location of the KRAS gene is on the short (p) arm of the 
chromosome 12 at the position 12.1. KRAS gene comprises four exons spanning 45 kb, more precisely from base pair 25.358.179 to 
base pair 25.403.869 on the chromosome 12. DNa sequencing of the exone 3 and a heterozygous missense variant at the codone 
179, conversing guanine to thymine (c.179G>t). the G>t conversion turns 179th triplet coding for glycine into valine (p.Gly60Val).
FiGure 3. raS-mitogen-activated protein kinase signaling pathway. extracellular ligand such as growth factor (GF) binds to GF re-
ceptor and activates cytoplasmatic part of the receptor (a tyrosine kinase), which by phosphorylation enables binding with docking 
proteins such as GrB2. this protein forms a complex with sons of sevenless (SoS) guanine nucleotide exchange factor and activates 
it. activated SoS removes guanosine diphosphate from raS protein and activates it. activated raS protein then activates rapidly 
accelerated fibrosarcoma (raF) kinase, and raF kinase subsequently activates MeK kinase (mitogen-activated protein [MaP] kinase 
kinase). MeK kinase finally activates mitogen-activated protein kinase MaPK, also known as extracellular signal regulated kinase. 
Mutations in genes controlling production of these signaling proteins, causing Noonan syndrome, are indicated (PTPN11, SOS1, 
KRAS, NRAS, SHOC2, RAF1, BRAF, MEK1).
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Patient’s clinical state deteriorated at the age of 28 days, 
when bacterial pneumonia developed; due to acute respi-
ratory failure he needed artificial ventilatory support for al-
most one month and for the same reason again at the age 
of 3 months. Cardiac function deteriorated significantly 
due to rapidly progressive hypertrophic cardiomyopathy 
and apart from ventilatory support he also received treat-
ment with propranolol and high doses of thiazide diuretics. 
As the heart disease was progressing rapidly and the diag-
nosis of NS was genetically confirmed, the parents agreed 
to withhold any further intensive treatment. He died at the 
age of four months due to a cardiorespiratory failure. The 
post-mortem autopsy was not performed.
DiSCuSSioN
There are three clinically important RAS genes in humans, 
HRAS, KRAS, and NRAS, encoding four RAS proteins (HRAS, 
KRAS 4A, KRAS 4B, and NRAS). These proteins are involved 
in the regulation of RAS – mitogen-activated protein ki-
nase (RAS-MAPK) pathway, which regulates cell growth, 
proliferation, differentiation, and apoptosis. RAS proteins 
are central signal transduction molecules, which act as 
molecular switches through cycling between an active, 
GTP-bound, and an inactive, GDP-bound state. The first re-
ports on mutations of RAS genes were from cancer stud-
ies and nowadays around 30% of all human cancers are 
known to have their origins in the mutation of one of the 
genes in the RAS-MAPK pathway, usually resulting in RAS 
hyperactivation (4).
Furthermore, germline KRAS mutations are also found in 
developmental diseases like NS, and the overall contribu-
tion of KRAS mutations to this disease is around 5% (5). In 
addition to KRAS mutations, many other germline RAS-
MAPK pathway mutations are also found in NS. Up to now, 
heterozygous germline mutations in seven different genes 
(PTPN11, SOS1, RAF1, SHOC2, KRAS, BRAF, NRAS) have been 
described. All these genes are encoding kinases and other 
proteins, and their mutations are connected with congen-
ital heart disease, feeding difficulties, developmental de-
lay, and short stature. These so called RASopathies include 
NS, cardio-facio-cutaneous syndrome, LEOPARD syndrome 
(lentigines, electrocardiographic anomalies, ocular hy-
pertelorism, pulmonary stenosis, abnormal genitalia, and 
deafness), and Costello syndrome (Figure 3).
There are several genotype-phenotype correlations in 
NS, but no phenotypic feature is exclusively related to a 
specific genotype. HCM is present in about 20% of NS pa-
tients, but rapidly progressive HCM, resulting in an ear-
ly death or a need for heart transplantation, occurs only 
sporadically in NS and other RASopathies. Described KRAS 
mutations (p.Lys5Asn, p.Val14Ile, p.Gln22Glu, p.Gln22Arg, 
p.Pro34Leu, p.Pro34Arg, p.Thr58Ile, p.Gly60Arg, p.Asp134Val, 
p.Phe156Leu, p.Val152Gly, and p.Asp153Val) are regularly 
associated with CHD (6-10). Extremely severe phenotype 
cases of NS and other RASopathies are typically caused 
only by specific mutations, resulting in overall signal flow 
dysregulation of the RAS-MAPK pathway (9,11,12).
We think that novel germline KRAS mutation due to 
heterozygous unclassified missense variant in exon 3: 
c.179G>T (p.Gly60Val) in our patient with clinical features 
of NS is very likely to be pathogenic, since other muta-
tions of the same amino acid (p.Gly60Ser and p.Gly60Arg) 
are known to be pathogenic mutations in NS (6,13). The 
malignant clinical course of the disease in our patient and 
the fatal outcome in just a few months might therefore 
be connected to RAS-MAPK pathway hyperactivation and 
consequently to rapidly progressive HCM.
In conclusion, KRAS mutation is a known cause of NS with 
usually mild clinical course. There are some rare excep-
tions, when a specific mutation of this gene causes a se-
vere phenotype with malignant clinical course, usually due 
to rapidly progressive HCM. The KRAS mutation c.179G>T 
(p.Gly60Val) identified in our patient might be associated 
with such lethal form of NS. Further biochemical and func-
tional studies are needed to confirm this hypothesis.
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